

## **Instructions for commenting on JIRA**

The JIRA comment tool will be used to collect comments on the electronic clinical quality measure entitled **Potential Opioid Overuse**. Please follow the below instructions for accessing the measure materials and for submitting your comment:

**To read the measure specifications, please visit:**

<https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/MMS/PC-Currently-Accepting-Comments.html>.

Please use the following links to submit your comments:

**If you are a current JIRA user with an active account:**

<https://oncprojecttracking.healthit.gov/>

(Select “Log In” at the top right corner.)

**If you are new to JIRA and do NOT have an account:**

<https://oncprojecttracking.healthit.gov/support/login.jsp>

(Select “Sign up” to set up a new account and log in to the JIRA tool.)

**Once logged in, enter your comments by following these instructions:**

1. Select “Projects” at the top middle of the home screen.
2. Select “View all Projects.”
3. Under Quality-Measures, select “Comments on eCQMs under development” project.
4. To enter comments, select “Create issue” (orange button) at the top middle of the screen.
5. Select the type of issue from the “Issue type” drop-down menu.
6. Fill out the fields labeled “Summary,” “Contact name,” “Contact email,” and “Contact phone.”
7. In the “Summary” field, type in the following title, “**Comment – Opioid**” for the Potential Opioid Overuse measure.
8. Enter your comments in the “Description” field.
9. Select “**Opioid**” from the “Draft measures” drop-down box
10. Select “Create” at the bottom left to submit your comments. If you would like to enter more comments, select “Create another” and then “Create.”

To be considered, comments must be submitted via the JIRA comment tool by 11:59 p.m. (EST) on February 9, 2018.

If you have any questions, please contact [e-measures@mathematica-mpr.com](mailto:e-measures@mathematica-mpr.com). For more information on using JIRA, please see the [JIRA User Guide](#).

Please circulate this email to any colleagues you feel would be interested in commenting on this measure. Thank you!